Effect of Polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the Pharmacokinetics of Lovastatin in Healthy Chinese Volunteers

References

• Liu Y , ZengBH , ShangHT , CenYY , WeiH . Bama miniature pigs (Sus scrofa domestica) as a model for drug evaluation for humans: comparison of in vitro metabolism and in vivo pharmacokinetics of lovastatin . Comp. Med.58 ( 6 ), 580 – 587 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Vyas KP , KariPH , PitzenbergerSMet al. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse . Drug Metab. Dispos.18 ( 2 ), 203 – 211 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Pierce LR , WysowskiDK , GrossTP . Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy . JAMA264 ( 1 ), 71 – 75 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Tobert JA . Efficacy and long-term adverse effect pattern of lovastatin . Am. J. Cardiol.62 ( 15 ), j28 – j34 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Tobert JA . Lovastatin and myopathy . Am. J. Med.96 ( 3 ), 300 – 301 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Yin OQ , MakVW , HuM , FokBS , ChowMS , TomlinsonB . Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in chinese subjects . Eur. J. Clin. Pharmacol.68 ( 6 ), 943 – 949 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ieiri I , HiguchiS , SugiyamaY . Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs . Expert. Opin. Drug Metab. Toxicol.5 ( 7 ), 703 – 729 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Keskitalo JE , ZolkO , FrommMF , KurkinenKJ , NeuvonenPJ , NiemiM . ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin . Clin. Pharmacol. Ther.86 ( 2 ), 197 – 203 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lee E , RyanS , BirminghamBet al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and asian subjects residing in the same environment . Clin. Pharmacol. Ther.78 ( 4 ), 330 – 341 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Zhu Y , D’agostinoJ , ZhangQY . Role of intestinal cytochrome p450 (p450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific p450 reductase knockout mouse . Drug Metab. Dispos.39 ( 6 ), 939 – 943 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kitzmiller JP , LuzumJA , BaldassarreD , KraussRM , MedinaMW . CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort . Pharmacogen. Genomics24 ( 10 ), 486 – 491 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wang X , WuX , WangCet al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells . FEBS Lett.584 ( 15 ), 3392 – 3397 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Birmingham BK , BujacSR , ElsbyRet al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in caucasian and asian subjects: a class effect? Eur. J. Clin. Pharmacol. 71 ( 3 ), 341 – 355 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kolovou G , RagiaG , KolovouVet al. Impact of CYP3A5 gene polymorphism on efficacy of simvastatin . Open Cardiovasc. Med. J.8 , 12 – 17 ( 2014 ).
   PubMedGoogle Scholar
• Becker ML , VisserLE , Van SchaikRH , HofmanA , UitterlindenAG , StrickerBH . Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy . Pharmacoepidemiol. Drug Saf.19 ( 1 ), 75 – 81 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Christians U , JacobsenW , FlorenLC . Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in transplant patients: are the statins mechanistically similar?Pharmacol. Ther.80 ( 1 ), 1 – 34 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Keskitalo JE , KurkinenKJ , NeuvonenPJ , NiemiM . ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin . Clin. Pharmacol. Ther.84 ( 4 ), 457 – 461 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , KantolaT , KivistoKT . Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole . Clin. Pharmacol. Ther.63 ( 3 ), 332 – 341 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Vree TB , DammersE , UlcI , Horkovics-KovatsS , RyskaM , MerkxI . Differences between lovastatin and simvastatin hydrolysis in healthy male and female volunteers: gut hydrolysis of lovastatin is twice that of simvastatin . ScientificWorldJournal3 , 1332 – 1343 ( 2003 ).
   Google Scholar
• Du J , XingQ , XuLet al. Systematic screening for polymorphisms in the CYP3A4 gene in the chinese population . Pharmacogenomics7 ( 6 ), 831 – 841 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• He BX , ShiL , QiuJ , ZengXH , ZhaoSJ . The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease . J. Clin. Pharmacol.54 ( 4 ), 462 – 467 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gao Y , ZhangLR , FuQ . CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin . Eur. J. Clin. Pharmacol.64 ( 9 ), 877 – 882 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hu M , MakVW , XiaoY , TomlinsonB . Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia . Pharmacogenomics14 ( 1 ), 25 – 34 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• CYP3A4 allele nomenclature . www.cypalleles.ki.se/cyp3a4.htm .
   Google Scholar
• Lamba J , LambaV , StromS , VenkataramananR , SchuetzE . Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression . Drug Metab. Dispos.36 ( 1 ), 169 – 181 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lehmann JM , MckeeDD , WatsonMA , WillsonTM , MooreJT , KliewerSA . The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions . J. Clin. Invest.102 ( 5 ), 1016 – 1023 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Gu X , KeS , LiuDet al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3a4 by proinflammatory agents . J. Biol. Chem.281 ( 26 ), 17882 – 17889 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Istrate MA , NusslerAK , EichelbaumM , BurkO . Regulation of CYP3A4 by pregnane X receptor: the role of nuclear receptors competing for response element binding . Biochem. Biophys. Res. Commun.393 ( 4 ), 688 – 693 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Klein K , ThomasM , WinterSet al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo . Clin. Pharmacol. Ther.91 ( 6 ), 1044 – 1052 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Piedade R , SchaeffelerE , WinterSet al. PXR variants and artemisinin use in vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin . Antimicrob. Agents Chemother.56 ( 4 ), 2153 – 2157 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lima LO , BruxelEM , HutzMHet al. Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy . Arq. Bras. Med. Vet. Zootec.57 ( 7 ), 513 – 519 ( 2013 ).
   Google Scholar
• Pasanen MK , NeuvonenM , NeuvonenPJ , NiemiM . SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid . Pharmacogen. Genomics16 ( 12 ), 873 – 879 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Zhang W , YuBN , HeYJet al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males . Clin. Chim. Acta373 ( 1–2 ), 99 – 103 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rodrigues AC , PerinPM , PurimSGet al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response . Int. J. Mol. Med.12 ( 9 ), 5815 – 5827 ( 2011 ).
   Google Scholar
• Oh ES , KimCOK , ChoSK , ParkMS , ChungJ-Y . Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans . Drug Metab. Pharmacokinet.28 ( 3 ), 196 – 202 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Niemi M , PasanenMK , NeuvonenPJ . SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin . Clin. Pharmacol. Ther.80 ( 4 ), 356 – 366 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Keskitalo JE , KurkinenKJ , NeuvonenM , BackmanJT , NeuvonenPJ , NiemiM . No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin . Br. J. Clin. Pharmacol.68 ( 2 ), 207 – 213 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Wang D , WangD , QinF , ChenL , LiF . Determination of lovastatin in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry . Biomed. Chromatogr. BMC22 ( 5 ), 511 – 518 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kitzmiller JP , SullivanDM , PhelpsMA , WangD , SadeeW . CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control . Drug Metab. Drug Interact.28 ( 1 ), 59 – 63 ( 2013 ).
   PubMedGoogle Scholar
• Lee JS , CheongHS , KimLHet al. Screening of genetic polymorphisms of CYP3A4 and CYP3A5 genes . Korean. J. Physiol. Pharmacol.17 ( 6 ), 479 – 484 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Li CJ , LiL , LinLet al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in chinese renal transplant recipients . PLoS ONE9 ( 1 ), e86206 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lunde I , BremerS , MidtvedtKet al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients . Eur. J. Clin. Pharmacol.70 ( 6 ), 685 – 693 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Miura M , SatohS , KagayaHet al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients . Pharmacogenomics12 ( 7 ), 977 – 984 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• De Keyser CE , BeckerML , UitterlindenAGet al. Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the rotterdam study . Pharmacogenomics14 ( 11 ), 1295 – 1304 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pasanen MK , FredriksonH , NeuvonenPJ , NiemiM . Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin . Clin. Pharmacol. Ther.82 ( 6 ), 726 – 733 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Karban AS , OkazakiT , PanhuysenCIet al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis . Hum. Mol. Genet.13 ( 1 ), 35 – 45 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Zhang Y , LiJL , FuQet al. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in chinese renal transplant recipients . Acta Pharmacol. Sin.34 ( 4 ), 555 – 560 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Schipani A , SiccardiM , D’avolioAet al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance . Antimicrob. Agents Chemother.54 ( 12 ), 5242 – 5250 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zhang J , KuehlP , GreenEDet al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants . Pharmacogenetics11 ( 7 ), 555 – 572 ( 2001 ).
   PubMedGoogle Scholar